HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism (for children under 1 year of age)
This study is now recruiting.
This study is a randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 7 days and 12 months who have congenital hyperinsulinism. Dasiglucagon will be given as a subcutaneous infusion while patients are admitted to the hospital. Other treatments for hyperinsulinism may be changed as allowed while maintaining safe blood sugar levels. For the second part of the study, patients may be able to go home on the medication.
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at mitteerl [at] chop.edu or 267-426-9915.
Eligibility & Criteria
IRB #:
18-014989
Official Title:
A Randomized Trial in 2 parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism
Study Phase:
Phase I
Phase II
Eligible Age Range:
0 Months - 12 Months
Gender:
All
Study Categories:
